WallStSmart

Cameco Corp (CCJ)vsUranium Royalty Corp (UROY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cameco Corp generates 6277% more annual revenue ($3.48B vs $54.60M). CCJ leads profitability with a 16.9% profit margin vs 8.0%. CCJ trades at a lower P/E of 108.0x. UROY earns a higher WallStSmart Score of 52/100 (C-).

CCJ

Buy

51

out of 100

Grade: C-

Growth: 8.0Profit: 6.5Value: 4.7Quality: 8.0
Piotroski: 5/9Altman Z: 2.42

UROY

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.5Value: 3.0Quality: 8.5
Piotroski: 2/9Altman Z: 151.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCJSignificantly Overvalued (-154.7%)

Margin of Safety

-154.7%

Fair Value

$46.80

Current Price

$109.02

$62.22 premium

UndervaluedFair: $46.80Overvalued
UROYSignificantly Overvalued (-189.3%)

Margin of Safety

-189.3%

Fair Value

$1.40

Current Price

$3.46

$2.06 premium

UndervaluedFair: $1.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCJ2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
45.3%8/10

Earnings expanding 45.3% YoY

UROY4 strengths · Avg: 9.5/10
Revenue GrowthGrowth
4164.0%10/10

Revenue surging 4164.0% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
151.3710/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

CCJ4 concerns · Avg: 3.5/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Price/BookValuation
9.4x4/10

Trading at 9.4x book value

Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

P/E RatioValuation
108.0x2/10

Premium valuation, high expectations priced in

UROY4 concerns · Avg: 3.3/10
EPS GrowthGrowth
4.6%4/10

4.6% earnings growth

Market CapQuality
$499.49M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.3%3/10

ROE of 1.3% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CCJ

The strongest argument for CCJ centers on Debt/Equity, EPS Growth. Profitability is solid with margins at 16.9% and operating margin at 13.6%.

Bull Case : UROY

The strongest argument for UROY centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 4164.0% demonstrates continued momentum.

Bear Case : CCJ

The primary concerns for CCJ are PEG Ratio, Price/Book, Revenue Growth. A P/E of 108.0x leaves little room for execution misses.

Bear Case : UROY

The primary concerns for UROY are EPS Growth, Market Cap, Return on Equity. A P/E of 113.7x leaves little room for execution misses.

Key Dynamics to Monitor

CCJ profiles as a value stock while UROY is a hypergrowth play — different risk/reward profiles.

UROY carries more volatility with a beta of 1.69 — expect wider price swings.

UROY is growing revenue faster at 4164.0% — sustainability is the question.

CCJ generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

UROY scores higher overall (52/100 vs 51/100) and 4164.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cameco Corp

ENERGY · URANIUM · USA

Cameco Corporation produces and sells uranium. The company is headquartered in Saskatoon, Canada.

Visit Website →

Uranium Royalty Corp

ENERGY · URANIUM · USA

Uranium Royalty Corp. The company is headquartered in Vancouver, Canada.

Visit Website →

Want to dig deeper into these stocks?